Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye

Cornea

Volumn 26, Issue 2, 2007, Pages 175-181

  Khanal, Santosh ^a   Tomlinson, Alan ^a   Pearce, Edward I ^a   Simmons, Peter A ^b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

Dry eye; Oil and water emulsion; Tear physiology

Indexed keywords

ARTELAC; CARBOMER; CASTOR OIL; DISODIUM HYDROGEN PHOSPHATE; EYE DROPS; GLYCEROL; HYDROXYPROPYLMETHYLCELLULOSE; POLYSORBATE 80; SODIUM DIHYDROGEN PHOSPHATE; SODIUM HYDROXIDE; SORBITOL; UNCLASSIFIED DRUG; WATER OIL CREAM;

ADULT; ANESTHESIA; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRY EYE; EMULSION; FEMALE; HUMAN; LACRIMAL FLUID; LIPID MEMBRANE; MAJOR CLINICAL STUDY; MALE; OSMOLALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SLIT LAMP; STATISTICAL SIGNIFICANCE; TEAR FILM;

ADULT; CASTOR OIL; DRY EYE SYNDROMES; EMULSIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFEROMETRY; MALE; METHYLCELLULOSE; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PATIENT COMPLIANCE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TEARS; TREATMENT OUTCOME; WATER;

EID: 33846516863     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31802b492d     Document Type: Article

References (51)

1. Foulks GN. The evolving treatment of dry eye. Ophthalmol Clin North Am. 2003;16:29-35.
2. Tomlinson A, Craig JP, Lowther GE. The biophysical role in tear regulation. Adv Exp Med Biol. 1998;438:371-380.
3. Yazdani C, McLaughlin T, Smeeding JE, et al. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672-1682.
4. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489-1496.
5. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492-496.
6. Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23: 784-792.
7. Gamache DA, McDonough TJ, Roberts L, et al. The mucin secretagogue 15(S)-HETE protects the cornea and improves tear film integrity in a rabbit model of lacrimal gland inflammation induced dry eye. Invest Ophthalmol Vis Sci. (ARVO E-Abstract). 2003;44:2498.
8. Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with sjogren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138:6-17.
9. Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211-222.
10. Isreb MA, Greiner JV, Korb DR, et al. Correlation of lipid layer thickness measurements with fluorescein tear film break-up time and schirmer's test. Eye. 2003;17:79-83.
11. Korb DR, Scaffidi RC, Greiner JV, et al. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. Optom Vis Sci. 2005;82:594-601.
12. Rieger G. Lipid-containing eye drops: a step closer to natural tears. Ophthalmologica. 1990;201:206-212.
13. Dinslage S, Stoffel W, Diestelhorst M, et al. Tolerability and safety of two new preservative-free tear film substitutes. Cornea. 2002;21:352-355.
14. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000;107:631-639.
15. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology. 2000;107:967-974.
16. Vehige JG, Carlisle C, Felix C, et al. Clinical trial results of a new emulsion-based dry eye treatment. Invest Ophthalmol Vis Sci. (ARVO E-Abstract). 2003;44:2449.
17. Pearce EI, Tomlinson A, Blades KJ, et al. Effect of an oil and water emulsion on tear evaporation rate. Adv Exp Med Biol. 2002;506:419-423.
18. Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology. 2004;111:783-791.
19. Maissa C, Guillon M, Chamberlain P. Effect of castor oil emulsion eyedrops on the tear film. Invest Ophthalmol Vis Sci. (ARVO E-Abstract). 2004;45:3900.
20. McMonnies CW. Key questions in a dry eye history. J Am Optom Assoc. 1986;57:512-517.
21. Hirji N, Patel S, Callander M. Human tear film pre-rupture phase time (TP-RPT)-a non-invasive technique for evaluating the pre-corneal tear film using a novel keratometer mire. Ophthalmic Physiol Opt. 1989;9:139-142.
22. Tomlinson A, Pearce EI, Simmons PA, et al. Effect of oral contraceptives on tear physiology. Ophthalmic Physiol Opt. 2001;21:9-16.
23. Trees GR, Tomlinson A. Effect of artificial tear solutions and saline on tear film evaporation. Optom Vis Sci. 1990;67:886-890.
24. Doane MG, Lee ME. Tear film interferometry as a diagnostic tool for evaluating normal and dry-eye tear film. Adv Exp Med Biol. 1998;438: 297-303.
25. Thai LC, Tomlinson A, Doane MG. Effect of contact lens materials on tear physiology. Optom Vis Sci. 2004;81:194-204.
26. Kok JH, Boets EP, van Best JA, et al. Fluorophotometric assessment of tear turnover under rigid contact lenses. Cornea. 1992;11:515-517.
27. Occhipinti JR, Mosier MA, LaMotte J, et al. Fluorophotometric measurement of human tear turnover rate. Curr Eye Res. 1988;7:995-1000.
28. Pearce EI, Keenan BP, McRory C. An improved fluorophotometric method for tear turnover assessment. Optom Vis Sci. 2001;78:30-36.
29. Craig JP, Simmons PA, Patel S, et al. Refractive index and osmolality of human tears. Optom Vis Sci. 1995;72:718-724.
30. Gilbard JP, Gray KL, Rossi SR. Improved technique for storage of tear microvolumes. Invest Ophthalmol Vis Sci. 1987;28:401-403.
31. Nelson JD, Wright JC. Tear film osmolality determination: an evaluation of potential errors in measurement. Curr Eye Res. 1986;5:677-681.
32. Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci. 1997;74:8-13.
33. Mathers WD, Daley TE. Tear flow and evaporation in patients with and without dry eye. Ophthalmology. 1996;103:664-669.
34. Mathers W. Evaporation from the ocular surface. Exp Eye Res. 2004;78: 389-394.
35. Mathers WD, Lane JA, Sutphin JE, et al. Model for ocular tear film function. Cornea. 1996;15:110-119.
36. Yokoi N, Komuro A. Non-invasive methods of assessing the tear film. Exp Eye Res. 2004;78:399-407.
37. Guillon JP. Abnormal lipid layers. Observation, differential diagnosis, and classification. Adv Exp Med Biol. 1998;438:309-313.
38. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci. 2000;41:3732-3742.
39. Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens. 2003;29:96-99.
40. Meadows DL, Paugh JR, Joshi A, et al. A novel method to evaluate residence time in humans using a nonpenetrating fluorescent tracer. Invest Ophthalmol Vis Sci. 2002;43:1032-1039.
41. Paugh JR, Chatelier RC, Huff JW. Ocular residence time of carboxymethylcellulose solutions. Adv Exp Med Biol. 1998;438: 761-767.
42. Snibson GR, Greaves JL, Soper ND, et al. Ocular surface residence times of artificial tear solutions. Cornea. 1992;11:288-293.
43. Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J. 2000;26:159-165.
44. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17:584-589.
45. Gilbard JP, Farris RL. Tear osmolarity and ocular surface disease in keratoconjunctivitis sicca. Arch Ophthalmol. 1979;97:1642-1646.
46. Farris RL. Tear osmolarity-a new gold standard? Adv Exp Med Biol. 1994; 350:495-503.
47. Farris RL, Gilbard JP, Stuchell RN, et al. Diagnostic tests in keratoconjunctivitis sicca. CLAO J. 1983;9:23-28.
48. Gilbard JP, Rossi SR, Heyda KG, et al. Stimulation of tear secretion and treatment of dry-eye disease with 3-isobutyl-1-methylxanthine. Arch Ophthalmol. 1991;109:672-676.
49. Gilbard JP, Rossi SR, Azar DT, et al. Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorders. CLAO J. 1989;15:216-218.
50. Gilbard JP, Rossi SR, Heyda KG. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. Am J Ophthalmol. 1989;107:348-355.
51. Tomlinson A, Khanal S, Rameash K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006;47:4309-4315.